SEATTLE, Feb. 21, 2017 /PRNewswire-USNewswire/ -- Concure Oncology, the parent company of Breast Microseed Treatment™, announces the appointment of Mona Lee Locke, former First Lady of Washington State and former Executive Director of Susan G. Komen Foundation, Puget Sound, to its Board of Directors: http://www.breastmicroseed.com/about-us/board-of-directors.aspx
By joining Concure's Board, Locke continues her fight against breast cancer. Having worked in breast cancer advocacy, education, research and treatment, Locke sees the impact Concure can have helping women with this disease (Breast Microseed Treatment is the single, one-hour radiation treatment option for early-stage breast cancer).
Mona Lee Locke is a former U.S. diplomat in Beijing, China and an Emmy-nominated, award winning television journalist with an extensive background in non-profit leadership. In addition, she served as the State Department's Special Advisor to the EducationUSA program in Beijing, co-chaired the Governor's Commission on Early Learning with Melinda Gates, and created the non-profit, Foundation for Early Learning. Later she worked at the Susan G. Komen Foundation, first, as the Executive Director of the Puget Sound affiliate, then as National Operations Director in Washington, D.C. With her diversity of experience, she brings a unique global perspective and expertise in the areas of education, government, cultural exchange, trade, communications, public affairs and women's leadership.
"I am very familiar with this space," said Locke. "I have strong ties to breast cancer, and this subject is near and dear to me. Because of my connection to so many survivors and volunteers through my work at Komen, I've heard the courageous stories of what women with breast cancer have gone through to survive this disease. I understand the difficulties associated with breast cancer treatment. Breast Microseed Treatment can change all of that for early-stage. It's a faster, easier, more convenient, and less painful way to treat it. I see it as an amazing option for women so that their lives, and the lives of their families aren't disrupted by this disease. I'm excited to be part of this team, and am passionate about getting the word out. Concure is really offering a public service here."
In confirming this appointment, CEO Sandra Rorem stated, "As we grow, I continue to be astonished by the level of expertise we have represented on our Board. We have quite a strong leadership representation already, and we couldn't be more pleased by this new appointment. Mona's deep professional background and passion 'for the cure' will bring an insightful perspective to the Board."
About Concure Oncology/Breast Microseed, Inc.
Concure Oncology is a medical device and services provider that includes Breast Microseed Treatment as part of its offering. Partnering with cancer centers to offer their treatment to patients with early-stage breast cancer, the company also offers end-to-end clinical support including physician proctoring, nursing and radiation therapist education, internal review board support, scientific advisory board oversight, patient flow and scheduling consultation, and inclusion in a national registry.
Breast Microseed Treatment - Focused on Life After Cancer
For more information on Concure Oncology and Breast Microseed Treatment, contact 844-BMS-INFO, or visit www.breastmicroseed.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/concure-oncology-announces-new-appointment-to-board-of-directors-300410233.html
SOURCE Concure Oncology/Breast Microseed, Inc.